The United Kingdom and the United States have concluded a key commercial pact that will ensure no duties on British medicine exports entering the American market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase spending on medicines through the public health system. This move secures that duties on these key products will stay at zero for a period of 36 months.
This deal follows previous statements to hike duties on patented pharmaceutical imports, with increases floated reaching one hundred percent.
"This arrangement between the UK strengthens the global environment for cutting-edge drugs and establishes long-overdue equity to transatlantic drug exports," an announcement noted.
Commercial Importance
Drugs are one of the the United Kingdom's most significant goods shipped to the America, which is by far the largest market for large British pharmaceutical firms.
Statistics reveal that in the one-year period leading up to the third quarter, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This figure made up a significant portion of all goods exports in that period.
"This guarantee protects jobs, increases funding and facilitates the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary commented.
Specific NHS Changes
The deal involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to double total public funding on treatments from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage manufacturers must refund to the NHS to stay within budget will be limited at 15%. Previously, repayments were more than 20%.
Industry Background
The deal comes amid a ongoing row between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
These tensions were exacerbated by arguments that US patients were charged significantly more for the same drugs than patients in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister publicly accepted that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had shrunk as a proportion of its total funding over the last ten years.
